|
|
Volumn 346, Issue , 2013, Pages
|
|
Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
GLUCAGON LIKE PEPTIDE 1;
SULFONYLUREA DERIVATIVE;
ANIMAL;
CHEMICALLY INDUCED DISORDER;
DRUG ANTAGONISM;
DRUG INDUSTRY;
DRUG SURVEILLANCE PROGRAM;
HUMAN;
INTERPERSONAL COMMUNICATION;
MASS MEDIUM;
NOTE;
PANCREAS TUMOR;
PANCREATITIS;
RISK ASSESSMENT;
ADVERSE DRUG REACTION REPORTING SYSTEMS;
ANIMALS;
DISCLOSURE;
DRUG INDUSTRY;
GLUCAGON-LIKE PEPTIDE 1;
HUMANS;
HYPOGLYCEMIC AGENTS;
MASS MEDIA;
PANCREATIC NEOPLASMS;
PANCREATITIS;
RISK ASSESSMENT;
SULFONYLUREA COMPOUNDS;
|
|
EID: 84880094856
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.f3900 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|
